Cetuximab Extends Survival In Advanced Non-Small Cell Lung Cancer
Robert Pirker
ROBERT PIRKER , Medical University of Vienna
Phase III study results have detected improvements in overall survival among patients with advanced non-small cell lung cancer treated with a monoclonal antibody targeted to the epidermal growth factor receptor: EGFR.
Phase III study results have detected improvements in overall survival among patients with advanced non-small cell lung cancer treated with a monoclonal antibody targeted to the epidermal growth factor receptor: EGFR.
